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Abstract
While advances in medicine, technology and healthcare services offer promises of longevity and
improved quality of life (QoL), there is also increasing reliance on a patient's skills and
motivation to optimize all the beneﬁts available. Patient engagement in their own healthcare
has been described as the ‘blockbuster drug of the century’. In multiple sclerosis (MS), patient
engagement is vital if outcomes for the patient, society and healthcare systems are to be
optimized. The MS in the 21st Century Steering Group devised a set of themes that require
action with regard to patient engagement in MS, namely: 1) setting and facilitating engagement
by education and conﬁdence-building; 2) increasing the importance placed on QoL and patient
concerns through patient-reported outcomes (PROs); 3) providing credible sources of accurate
information; 4) encouraging treatment adherence through engagement; and 5) empowering
through a sense of responsibility. Group members independently researched and contributed
examples of patient engagement strategies from several countries and examined interventions
that have worked well in areas of patient engagement in MS, and other chronic illnesses. The
group presents their perspective on these programs, discusses the barriers to achieving patient
engagement, and suggests practical strategies for overcoming these barriers. With an under-
standing of the issues that inﬂuence patient engagement in MS, we can start to investigate ways
to enhance engagement and subsequent health outcomes. Engaging patients involves a broad,
multidisciplinary approach.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
In 2011, the multiple sclerosis in the 21st Century initiative
was established; it is led by a Steering Group of international
experts in MS treatment and management, and by patient
group representatives. The initiative seeks to deﬁne MS treat-
ment and standards of care for the 21st century, develop a
minimum standard of care internationally, and motivate the
MS community to align standards of care and challenge the
current treatment paradigm. Towards that aim, the Steering
Group developed overarching principles to guide management
and improve outcomes for people with MS, which were
published in their 2012 consensus statement (Rieckmann
et al., 2013). Among those principles, the group identiﬁed
the patient-centric elements as requiring the most urgent
action – in particular, the topic of patient engagement in MS.
2. Methods
Two workshops were held to identify themes related to
patient engagement that the group felt were of particular
importance in the ﬁeld of MS. In addition to the original
Steering Group members, the workshops involved a diverse
pool of important stakeholders in MS care including neurol-
ogists, an MS nurse, a health economic specialist, a patient
group representative, a neuro-rehabilitation specialist and a
neuropsychologist.
Five themes were prioritized through discussion and
debate, and they constitute the basis of this publication.
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Group members independently researched and contributed
examples of patient engagement strategies from several
countries. Through two additional videoconferences, the
group examined interventions that have been successful in
areas of patient engagement – not merely in the ﬁeld of MS,
but also in other chronic illnesses that may have overlapping
issues with MS. In this publication, the group presents their
perspective on these programs, discusses research demon-
strating the barriers to achieving patient engagement,
and provides practical strategies for overcoming these
issues.
3. What is patient engagement?
While advances in medicine, technology and healthcare
services continue to offer promises of longevity and
improved quality of life (QoL), reliance on the patient's
knowledge, skills and motivation to access these beneﬁts is
increasing. The reasons for this may lie in the need to
streamline health services and minimize burden on health-
care providers, fragmented healthcare delivery systems,
and the movement away from a paternalistic/authoritarian
style of healthcare arising from evidence that patients have
better health outcomes when they play a role in their own
healthcare (Center for Advancing Health, 2014). The US
Center for Advancing Health deﬁnes patient engagement
(sometimes known as ‘patient activation’) as ‘actions
individuals must take to obtain the greatest beneﬁt from
the healthcare services available to them’ (Center for
Advancing Health, 2014). Certainly, with a chronic illness
such as MS where novel therapies will most likely inﬂuence
multiple body systems, a multidisciplinary approach for
effective healthcare management is crucial. As such, a
‘linchpin’ is required to ensure the various sources of care
and treatment are coordinated; the concept of patient
engagement asserts the patient as that linchpin.
Just as patients are required to change their role from
healthcare ‘receiver’ to ‘engager’, the role of the health-
care professional also needs to evolve from being a ‘provi-
der’ of healthcare to become a ‘motivator’ and ‘supporter’
of patients to help them achieve this.
4. Why is patient engagement so important?
Patient engagement can be practiced at the macro (sys-
tem), meso (institution), and micro (medical encounter)
levels. However, only some patients will wish to be involved
at macro or meso levels.
Patient engagement is particularly important in a chronic
illness such as MS, which necessitates lifelong therapy.
Patients face decisions relating to treatment, interventions
and services available, and QoL (Heesen et al., 2011; von
Puckler, 2013). Previously, interferon beta or glatiramer
acetate therapy was the mainstay of treatment for MS,
(National Collaborating Centre for Chronic Conditions, 2004)
and their side effects were well known, reversible, pre-
dictable, and treatable (Coyle, 2009). However, in the last
10 years, new treatments have emerged which, although
beneﬁcial from an efﬁcacy or ease of administration per-
spective, also have the potential to cause serious side
effects (Girouard and Soucy, 2011; Kieseier et al., 2011). It
is imperative that these evolving risks and their relationship
to clinical beneﬁt are taken into account by the patient
(Clanet et al., 2014).
Patients can play an integral role in improving the quality,
safety, and cost of healthcare interventions. As such, the
patient has been described as the ‘greatest untapped
resource in healthcare’, and patient engagement termed
‘the blockbuster drug of the century' (Chase, 2013). Furth-
ermore, the importance of patient engagement as an
essential component of high quality healthcare has been
recognized worldwide (Department of Health, 2005a;
Aljumah et al., 2013; Institute of Medicine 2014, 2012;
Chow et al., 2009). The list of parameters shown to be
inﬂuenced by patient engagement is extensive and includes
improved clinical outcomes, reduced healthcare consump-
tion and improved service quality (Department of Health,
2005a; Chow et al., 2009; Institute of Medicine, 1999; Jha
et al., 2008; Meterko et al., 2010; Glickman et al., 2010;
Isaac et al., 2010; Charmel and Frampton, 2008; Pietrolongo
et al., 2013; Heesen et al., 2013; Coulter, 2012). Improved
clinical outcomes shown to equate with patient engagement
include improved treatment adherence, faster recovery and
reduced mortality rates (Department of Health, 2005a;
Chow et al., 2009; Institute of Medicine, 1999; Jha et al.,
2008; Meterko et al., 2010; Glickman et al., 2010; Isaac
et al., 2010; Charmel and Frampton, 2008; Pietrolongo
et al., 2013; Heesen et al., 2013; Coulter, 2012) An analysis
of 41800 veterans with myocardial infarction showed that
better patient-centered care was associated with a lower
hazard of death over a 1-year study period (HR: 0.992; 95%
CI: 0.986–0.999) (Meterko et al., 2010).
When patients are engaged with their healthcare, both
reduced healthcare consumption (including improved health
service efﬁciency, fewer diagnostic tests and referrals,
decreased use of healthcare services and lower annual
charges) and patient preference towards less aggressive/
costly courses of treatment are seen (Department of
Health, 2005a; Chow et al., 2009; Institute of Medicine,
1999; Jha et al., 2008; Meterko et al., 2010; Glickman
et al., 2010; Isaac et al., 2010; Charmel and Frampton 2008;
Pietrolongo et al., 2013; Heesen et al., 2013; Coulter,
2012). For example, patients who are properly informed
about their treatment options are less likely to opt for
expensive elective surgical procedures where other options
exist (Isaac et al., 2010). Improved service quality is
observed when patients are engaged, and can include
improved communication and health literacy, greater con-
ﬁdence in treatment decisions, decreased malpractice
claims, higher hospital staff retention rates, more satisﬁed
patients, and reduced patient–physician discordance
(Department of Health, 2005a; Chow et al., 2009; Instit-
ute of Medicine, 1999; Jha et al., 2008; Meterko et al.,
2010; Glickman et al., 2010; Isaac et al., 2010; Charmel and
Frampton, 2008; Pietrolongo et al., 2013; Heesen et al.,
2013; Coulter, 2012). In Stamford Hospital, 18 months after
implementing a structured approach to patient-centered
care, the employee satisfaction rate increased from the 33rd
to the 60th percentile (Charmel and Frampton, 2008). With
so much to be gained from patient engagement, efforts to
promote this untapped resource are paramount.
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5. What inﬂuences patient engagement?
Understanding of patient engagement in MS is in its infancy
but the factors inﬂuencing engagement appear complex
and diverse. One cross-sectional survey of 199 MS patients
in Southeast USA, identiﬁed that MS-related QoL and MS-
related self-efﬁcacy correlated signiﬁcantly with patient
activation in MS patients (r=0.42, Po0.01 and r=0.50,
Po0.01, respectively). Depression had an inverse correla-
tion (r=0.43; Po0.01) (Goodworth et al., 2014). Studies
in other disease areas have demonstrated further elements
that may play a role. One review reported ﬁve categories
of factors inﬂuencing engagement: patient-related (pat-
ents' knowledge/beliefs, demographic characteristics,
emotions and coping style); illness-related (symptoms,
treatment plan, patient's prior experience, illness sever-
ity); healthcare professional (HCP)-related (HCPs’ knowl-
edge and beliefs, HCP role); healthcare setting-related
(primary or secondary care); and task-related (medical
knowledge required and whether the required patient
behavior challenges clinicians' clinical abilities) (Davis
et al., 2007).
Table 1 Interventions shown to support shared decision-making and health literacya.
Intervention Potential beneﬁts
Shared decision-making
Patient decision aids  Increased patient involvement in decisions
 Better understanding of treatment options
 More accurate perception of risks
 Improved quality of decisions
 Does not increase patient's anxiety
Health coaching  Reduced mortality
 Reduced risk factors
 Improved health status
Question prompts  Increased question-asking in consultations
 May increase patients' knowledge and understanding
 May empower patients and improve satisfaction
 Does not necessarily increase length of
consultations
Self-management education and support  Improved patient knowledge and understanding
 Improved conﬁdence and coping ability
 Improved health behaviors
 Improved social support
 May improve adherence to treatment
recommendations
 May improve health outcomes
 May reduce hospital admission rates
Health literacy
Personalized patient information (paper and electronic) reinforced
by professional or lay support
 Improvements in patients’ knowledge and
understanding of their condition
 Increased sense of empowerment
 Greater ability to cope with the effects of illness
 Improved patient satisfaction
 May lead to improvements in health behavior
 May contribute to better health outcomes
Telephone counseling and help lines  Less social isolation
 Improved self-efﬁcacy and satisfaction
 Reduced mortality and fewer hospitalizations for
some patient groups
 May improve diagnostic accuracy
 May contribute to improved health status and
better QoL
Motivational interviewing  Better adherence to treatment recommendations
 Improved health behavior
 Reduced risk factors
 Improved health outcomes
aReproduced and adapted from Coulter et al. Patient engagement–what works? The Journal of Ambulatory Care Management
2012;35:80-9 (Coulter, 2012). Where the evidence is less strong, this is indicated by including may in the list of potential beneﬁts.
205Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century
6. Achieving patient engagement
Understanding the issues that inﬂuence patient engagement
in MS will facilitate investigation into how these might be
overcome.
6.1. Theme 1: setting and facilitating engagement
by education and conﬁdence-building
A prerequisite to helping a patient become engaged is the
establishment of an effective, caring and mutually respect-
ful patient–physician relationship; patients consistently say
that good communication with their doctors boosts their
conﬁdence with the healthcare process (von Puckler, 2013;
Duffy et al., 2004). People prefer to be treated by clinicians
who are empathetic listeners and who are good at inform-
ing, advising, and educating them (Coulter, 2005; Keating
et al., 2002). Moreover, the main independent predictors of
patient satisfaction are patients’ perceptions of commu-
nication and partnership, and a positive approach by the
doctor (Little et al., 2001). One study demonstrated that
therapist responsiveness in the ﬁrst two sessions of therapy
relates to three measures of early patient engagement in
treatment. Using videotapes and data from the NIMH
(National Institute of Mental Health) Treatment of Depres-
sion Collaborative Research Program (TDCRP), an instru-
ment was developed to measure therapist responsiveness in
the ﬁrst two sessions of Cognitive Behavior Therapy and
Interpersonal Psychotherapy. A factor measuring positive
therapeutic atmosphere, and a global item of therapist
responsiveness, predicted both the patient's positive per-
ception of the therapeutic relationship after the second
session and the number of patient's remaining in therapy
for more than four sessions. A negative therapist behavior
factor also predicted early termination (Elkin et al., 2014).
Engagement is vital from the day of diagnosis,(Solari 2014)
when the MS patient and their physician embark on a unique
journey together and the emotional burden on both parties
is high (Solari, 2014). Consequently, the collaborative
nature of that initial process and the success in instigating
clear, honest communication can determine whether the
future relationship will be one of trust and respect and how
positively the patient will be involved in their health
decisions and management.
There is growing acknowledgment that healthcare pro-
fessionals require effective communication and conﬂict
management skills,(Ha and Longnecker, 2010) despite some
receiving little or no focused training in these areas. Some
studies point to the need for further empowerment of MS
physicians to gain better patient communication skills
(Pietrolongo et al., 2013; Kasper et al., 2011; Kasper
et al., 2008). Encouragingly though there is evidence that
communication skills training is becoming more visible in
medical education. Such training is well established in
medical schools across the UK, Europe and the USA
(Hausberg et al., 2012). In the USA, communication skills
feature prominently in clinical skills examinations and are
incorporated into residency programs and maintenance
certiﬁcation of practicing physicians (Makoul 2003).
Various practical strategies have been proposed to optimize
physician–patient communication. Simple conversational and
listening techniques can be helpful, eg sitting down during a
consultation, attending to patient comfort, establishing eye
contact, listening without interrupting, showing attention with
nonverbal cues such as nodding, allowing silences while patients
search for words, acknowledging and legitimizing feelings,
explaining and reassuring during examinations, and asking
explicitly if there are other areas of concern. The provision of
‘prompt sheets’ encourages patients to ask questions about
their treatment options, patients can be encouraged to bring a
list of questions to their clinic visits. Directing patients to access
their medical notes promotes transparency and trust, and
improves information recall. Tools such as www.myopennotes.
org provide help in achieving this and, in fact, the patient's
right to access their medical notes has been legalized in France
through the Kouchner Act, 2004 (http://lelien.typepad.fr/
association_le_lien/2007/12/accs-aux-inform.html). However,
patients with low levels of health literacy may ﬁnd this initially
challenging. A ‘road map’ or a set of goals that both physician
and patient wish to achieve can be developed and amended
throughout the disease course. Shea (2006) also describes a
number of useful techniques, such as: learning the patient's
belief set; familiarization with the patient's family history/
cultural beliefs to discover underlying motivations; providing
the patient with a sense of collaboration in the health decision
process; and learning the patient's opinion towards taking
medication in general (Shea, 2006). In addition, reliable,
up-to-date publications and guidance to support physicians in
communicating with their patients are provided by the MS
Society. Coulter (2012) also provides initiatives that have
proven beneﬁcial (Table 1) (Coulter 2012) and Table A1
(Appendix) provides examples that support the use of these
initiatives. The Adopt One! Challenge http://mindthegap.
smarthealthmessaging.com/2013/08/13/the-adopt-one-challen
ge-the-ﬁrst-step-to-better-patient-engagement-patient-experie
nces-2/ allows physicians to obtain a comprehensive baseline
assessment of their patient communication skills, measure how
their skills compare with best practice, and access online skills
development tools. The program encourages physicians to
commit to adopting one new patient-centered communication
skill over the course of 12 months and provides online training
and resources needed to help them achieve this goal.
Current management guidelines underline the importance
of educating and supporting the MS patient. National Institute
for Clinical Excellence (NICE) guidelines recommend imple-
menting an education program that takes into account the
different aspects of the disease and incorporates guidance on
the level of communication, provision of emotional support,
encouragement of autonomy/self-management and provision
of support to family and carers; http://www.nice.org.uk/
nicemedia/live/10930/46699/46699.pdf. The European MS
Platform's Code of Good Practice (http://www.emsp.org/
attachments/article/134/1code08.pdf) stresses the impor
tance of accessible information, informed advice and emo
tional support, and suggests self-help education programs be
provided for patients and their carers. The concept of
‘therapeutic patient education’ has also been enshrined in
French law (article 84, Hospitals, Patients, Health and Terri
tory, Law No. 2009-879 of 21 July 2009) and is ofﬁcially
recognized as an integral part of patient care. Speciﬁcally, it
mandates that patients must receive specialized education
related to their condition, which can be delivered by trained
‘peer educators’.
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Table 2 Research and development studies evaluating the symptoms of MS that commonly impact on QoL and HR-QoL in MS
patients.
Study Outcome measured Findings related to the impact on patient
QoL/HR-QoL
Vision impairments
(Galetta et al., 2012) EDSS: visual function Visual dysfunction in benign MS was as marked
as that in typical MS and accounted for a
substantial degree of disability and loss of QoL
(Galetta et al., 2012).
(Mowry et al., 2009) Low contrast letter acuity Speciﬁc visual disorders measured by low
contrast letter acuity may inﬂuence QoL
(Mowry et al., 2009)
Gait and mobility impairments
(Van Asch 2011) Anonymous online survey on
walking and mobility
45% of patients reported mobility difﬁculties
within 1 month of diagnosis, 93% within 10
years. These had a profound effect on
independence, employment, loss of earning,
HRQoL and ADLs
(Yildiz 2012) Online 5-question survey
evaluating walking speed
Impaired walking speed affected ADLs and
avoidance of: walking to the nearest shop
(53%), cleaning the home (46%), crossing the
street (31%), walking to the post box (29%),
visiting neighbors (24%)
Sexual dysfunction
(Nortvedt et al.,
2001)
SF-36 Health Survey Present in up 91% of MS patients. May be a
direct reﬂection of MS neurological
impairments, side effects of treatments, or
indirect changes in sexual responsiveness due
to other MS symptoms (eg fatigue, depression,
bowel and bladder dysfunction, mobility issues,
etc) (Burks et al., 2009). Patients with sexual
dysfunction scored lower on all 8 subscales of
SF-36, after adjustment for EDSS (Nortvedt
et al., 2001). Most signiﬁcant effects on QoL:
perceived social functioning, vitality, perceived
general health, depression, ability to form
intimate relationships (Burks et al., 2009)
(Burks et al., 2009) None (overview)
Mental health problems
(Hart et al., 2005) MSQoL-54, Ryff's Scales of
Psychological Well-being:
depression
Depression affects HR-QoL, possibly more than
physical disability/symptoms. Treatment of
major depression signiﬁcantly improved
psychological well-being
(Phillips et al., 2009) Emotional Regulation
Questionnaire, WHOQoL-
BREF: emotional adjustment
Failure to use effective emotional reappraisal
strategies reduced all aspects of QoL
(Kern et al., 2009) Symptom Checklist-90-R:
psychological distress
Psychological distress in MS patients is
associated with neurological disability, but is
also present in patients with minimal or no
neurological disability. Psychological distress is
an independent predictor for MS-related QoL
Cognitive dysfunction
(Rao et al., 1991) A comprehensive
neuropsychological test
battery
Cognitive dysfunction impacted many aspects
of daily functioning, eg work, social and
avocational activities, sexual dysfunction,
performance of household tasks,
psychopathology (Rao et al., 1991).
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6.2. Theme 2: patient-reported outcomes:
increasing the importance placed on QoL and
patient concerns
MS patients rank their QoL as lower than the general public,
and lower than those with other chronic diseases (Rudick et al.,
1992; Riazi et al., 2003; Burden of illness of multiple sclerosis,
1998). The wide-ranging effects of MS impact an individual's
QoL at psychological, physical, social and ﬁnancial levels,
throughout all stages of the disease (Miller and Allen 2010;
Mitchell et al., 2005). However, clinical focus on MS has relied
heavily on the Expanded Disability Scale Score (EDSS) – a
measure of disease activity weighted towards the physical,
especially mobility, aspects of the disease (Kurtzke, 1983).
More recently, however, the importance of MS outcome assess-
ment from the patient's perspective has been recognized.
Patient-reported outcomes (PROs) include information provided
by the patient that reﬂects their functioning health and well-
being from their perspective, including how the disease and
medical interventions impact on their QoL. PROs introduce a
more holistic approach to disease management by incorporat-
ing outcomes affecting the patient across many aspects of their
QoL. The diverse subjective symptoms associated with loss of
QoL are difﬁcult to quantify, hence discrepancies arise between
patient and physician perceptions over which domains of health
are the most crucial (Rothwell et al., 1997). Nonetheless,
patients report symptoms earlier and more frequently than
clinicians do,(Basch, 2010) and patients’ reports are more
highly concordant with overall health status than clinicians’
reports (Basch, 2010). Integrating PROs into clinical practice
has the potential to capture those beneﬁts and enrich the
clinical encounter (Miller and Allen, 2010).
Table 2 (continued )
Study Outcome measured Findings related to the impact on patient
QoL/HR-QoL
(Fernandez et al.,
2011)
MS International QoL
Questionnaire (MuSiQoL)
Cognitive dysfunction is a major factor in
determining QoL in MS (Rao et al., 1991;
Fernandez et al., 2011) Limitations in a
patient's work and social activities correlated
with cognitive decline, independent of the
degree of physical disability (Amato et al.,
2001)
(Amato et al., 2001) A neuropsychological test
battery
Attention deﬁcit
(Phillips et al., 2009) Cognitive Failures
Questionnaire: attentional
lapses
Attentional failures – predicted variance in all
aspects of QoL (WHOQoL-BREF)
Bladder and bowel problems
(Vitkova et al., 2013) Bladder Control Scale,
Bowel Control Scale,
Incapacity Status Scale
Bladder dysfunction is associated with a poorer
HR-QoL in MS patients even if they have had MS
for a relatively short time
Fatigue
(Zwibel 2009) Review of PubMed searches
on multiple contributors to
QoL in MS
Fatigue is present in 75–95% of MS patients
(Zwibel 2009). Affects physical and mental
components of QoL, independent of disability.
Impairs vocational abilities and stamina for
physical activity; primary cause of MS-related
unemployment (Zwibel 2009; Nogueira et al.,
2009)
(Nogueira et al.,
2009)
Fatigue Severity Scale
Pain
(Svendsen et al.,
2005)
SF-36: pain Pain in MS is associated with pressure pain
threshold, cold allodynia, abnormal temporal
summation, and mechanical or thermal
hyperalgesia. Pain patients scored lower in all
dimensions of SF-36 compared with pain-free
and healthy subjects
Sleep disturbances
(Merlino et al., 2009) Pittsburgh Sleep Quality
Index (PSQI), Charlson
Comorbidity Index (CCI), SF-
36 Italian version
Poor sleep present in almost 50% of MS patients.
Independent predictor of QoL on various
measures of QoL. Can result from pain, bladder
and sexual dysfunction and other clinical
conditions
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The major factors contributing to health-related QoL (HR-
QoL) of the MS patient include the ability to perform
activities of daily living (ADLs), patient well-being, satisfac-
tion with life, and the impact of disease-related symptoms
on these parameters (Burden of illness of multiple sclerosis,
1998). Table 2 shows the results from selected studies that
have investigated the symptoms of MS that commonly
impact on QoL and HR-QoL in MS patients. The challenge
to the physician is to identify a management plan to address
the range of symptoms impacting each individual's QoL.
To date, numerous PRO QoL measures have been devel-
oped speciﬁcally for MS,(Vickrey et al., 1995; Cella et al.,
1996; Ritvo et al., 1997; Hobart et al., 2001; Ford et al.,
2001; Doward et al., 2009; Meads et al., 2009) but no
particular measure has gained wide popularity or consensus
(Solari, 2005). There are practical considerations when
incorporating a PRO measure into clinical practice. These
include deciding which measure to use and the frequency
with which it should be conducted, ﬁnding an appropriate
setting and mode of administration, identifying aids to
interpret the data, achieving the ‘buy-in’ of institute staff
and patients, sourcing and maintaining appropriate equip-
ment, minimizing disruption to healthcare delivery, and
allowing sufﬁcient time for implementation.
Both digital-based technology and more traditional inter-
view methods may have a role in PRO measurement and
should be evaluated for acceptability in the environment in
which they are to be used. The Multiple Sclerosis Documen-
tation System 3D (MSDS 3D) is an innovative computer-based
documentation system being used successfully in clinical
practice in Germany to integrate data provided by the
patient, the MS nurse and the physician (Schultheiss et al.,
2012; Ziemssen et al., 2013).
Incorporation of PRO QoL measures in clinical practice is
likely to escalate as our understanding of them increases.
Already, they have been included as a central element of
healthcare evaluation and health service evaluation, dis-
ease registries, epidemiological studies, drug R&D, and
clinical trials (Riazi, 2006).
6.3. Theme 3: providing credible sources of
accurate information
Considering the complexity of MS disease pathology and the
intricacy of the management options available, provision of
trusted, accurate and relevant information is paramount to
an MS patient (von Puckler, 2013). A recent Cochrane review
determined that information provision to people with MS
increased disease-related knowledge with no negative side
effects (Köpke et al., 2014). In 65% of clinic visits the
patient's desire for health information is underestimated
(Waitzkin, 1984). One study highlighted a deﬁcit between
the information patients were receiving and the amount of
information they actually wished to receive from various
sources. While the amount of information provided by MS
societies and MS specialist nurses was considered close to
ideal, many patients wished to receive signiﬁcantly more
information from GPs, eye specialists, neurologists, and
from education sessions (Matti et al., 2010).
Unsurprisingly, mass media, rather than interpersonal infor-
mation sources, are the ﬁrst route of information accessed by
many people with MS concerns (Marrie et al., 2013). However,
understandably, many patients have concerns about the quality
of that information (Marrie et al., 2013). One study showed that
the most trusted information source was the physician, with
98% reporting that they trusted a physician ‘some’ or ‘a lot’
(Marrie et al., 2013). In another study, two-thirds of patients
were reluctant to discuss internet information with their
physician (Hay et al., 2008). Therefore, some patients are
exposed to information that is not reliable, and of which their
physicians are not aware, nor able to provide their reaction or
opinion (Ball and Lillis, 2001; Potts and Wyatt, 2002). A possible
barrier to discussing internet-derived information is fear of
perceived lack of conﬁdence in the physician. Consequently,
the MS physician needs to be prepared to open discussions
regarding the accuracy and reliability of this source of informa-
tion from the ﬁrst consultation, and to reassure the patient that
they are open to discussing information they access.
Internet-based information can help bridge the gap between
doctor and patient and elevate the level of dialog. However,
lack of quality control of such information has led to the
development of health website evaluation tools to help direct
patients to accurate sources of information. These tools have
revealed excellent websites that can meet nearly all of the
information needs of people with MS (Harland and Bath, 2007).
To our knowledge, there is currently no widely acknowledged
quality certiﬁcation for MS websites, although these do exist in
other disease areas. One such scheme undertaken by a French
rheumatoid arthritis (RA) patient organization provides a qua-
lity rating for RA websites that is arbitrated by both health pro
fessionals and patients (http://www.polyarthrite-andar.com/
article171.html). This is possibly an area for future focus in MS.
Patients can be supported to self-regulate the information
they access and how they interpret it. Some websites provide
useful commentary by MS experts, helping patients interpret
trial data and understand their likely impact (http://multi
ple-sclerosis-research.blogspot.co.uk/). The Multiple Sclerosis
International Federation (MSIF) has published guidance for
patients on issues to consider when assessing online content
regarding MS,(Shaw, 2014) which includes:
 check who is responsible for developing the content of
the website and consider their reasons for providing the
information;
 check whether the content seems reliable, complete and
current, and check against other sources;
 check that the website presents a broad and unbiased
view in an easy-to-read format;
 check that the website's privacy policy and disclaimers
are clear and accessible;
 even if a website looks professional it does not mean it
is, check its credentials;
 check the website's country of origin; treatments or
services may not be available in every country.
As well as the risk of misinformation, unfettered access to
MS information has the potential to overwhelm a patient and
cause them anxiety. To help avoid this, information regarding
MS can be sensitively phased or layered in topic, rate and
complexity, depending on the desire and needs of the indivi-
dual patient. Modern technology allows an effective and cost
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-efﬁcient way to achieve this. Giovannoni's ‘tube map’ for MS
care highlights what information and support is required
throughout all stages of the disease (Fig. 1).
Owing to the complexity of MS, helping a patient to improve
their health literacy – the capacity of the patient to obtain,
process and understand basic health information and services
needed to make appropriate health decisions – is beneﬁcial.
Interventions associated with improved health literacy are
shown in Table 1 (Coulter, 2012). However, the impact of
information is greater when accompanied by verbal reinforce-
ment by a physician (Coulter, 2012) – and the MS physician and
their medical team are in the ideal position to act as a trusted
sounding board for a patient with MS.
One way of supplementing the education and support
provided by physicians and MS nurses is through specialist
MS group therapeutic education programs, which can take
the form of group seminars or workshops, and may reinforce
disease and treatment information, physical rehabilitation
and psychological counseling. They have been shown to
improve patient coping strategies, patient satisfaction,
psychological difﬁculties, QoL and treatment persistence
(Colpaert, 2010; Gallien et al., 2014; Mazaheri et al., 2011;
Rat, 2013). These may represent a resource-effective way
of providing additional information to MS patients, but
analysis on cost-effectiveness and ways to ensure uptake
across sub-populations are required (Plow et al., 2010).
6.4. Theme 4: encouraging treatment adherence
through engagement
With the availability of disease-modifying therapies for MS,
problems with adherence to these complex treatment regi-
mens under chronic conditions have been observed (Klauer
and Zettl, 2008). In developed countries, treatment adher-
ence among patients with MS is a mere 41% (Steinberg
et al., 2010). Considering that lack of adherence to inter-
feron beta treatment in MS correlates with a loss of efﬁcacy,
higher relapse rate and higher utilization of health
resources,(Steinberg et al., 2010) this remains an area for
concern for treating physicians (Martin et al., 2005).
The causes of non-adherence in MS are complex and are
reported to include forgetting medication, MS-related disability
affecting ability to medicate, patient disagreement with need
for treatment, cost, poor social support (Girouard and Soucy,
2011; Martin et al., 2005; Lugaresi et al., 2012; Cerghet et al.,
Fig. 1 Multiple sclerosis tube map.a Redrawn and adapted with permission of Professor Gavin Giovannoni. © Gavin Giovannoni.
The schematic demonstrates the breadth of information required by the MS patient throughout the course of their illness. To
optimize the impact, information can be layered to a rate and depth relevant to the individual patient. Forthcoming versions of the
tube map will include such layering.
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2010; Saunders et al., 2010) and patients forgetting to take
their medication Treadaway et al., 2009. However, sometimes
treatment adherence reﬂects the interpersonal dynamics of the
physician–patient relationship (Martin et al., 2005). In the ﬁeld
of HIV there is evidence to suggest that good physician–patient
relationships are correlated with better adherence to antire-
troviral regimens. A small Italian study suggests that this may
also be the case in MS. Patient-perceived utility of treatment
signiﬁcantly correlated with patients having conﬁdence in the
clinical staff, to their perception of being involved in ther-
apeutic decision making (Po0.05), and to long-term therapy
adherence (P=0.0001) (Koudriavtseva et al., 2012). Other
studies have shown that the aspects of the physician–patient
relationship associated with higher rates of therapy adherence
include general communication, overall satisfaction, willingness
to recommend, physician trust, disease-speciﬁc communica-
tion, and adherence dialog (Schneider et al., 2004).
The goals of the healthcare professional, with respect to
adherence, could be to motivate the patient to take the
medication correctly, to adhere to the prescribed schedule
and to keep follow-up appointments. Other support strate-
gies might include sending reminders, providing information
that the patient can consult after the appointment, helping
the patient understand the importance of adherence,
listening to individual concerns, and offering praise and
encouragement (Kinnersley et al., 2007; Smrtka et al.,
2010). Remington et al. provide a thorough list of possible
interventions to promote adherence in MS (Remington
et al., 2013). Various methods have demonstrated efﬁcacy
in improving adherence to therapy in MS. Several studies
have reported an association between improved adherence
and nurse-based telephone counseling;(Caon et al., 2010)
motivational interviewing has also had a beneﬁcial effect on
adherence (Caon et al., 2010). Telephone-based CBT for the
treatment of depressive symptoms has shown to be more
efﬁcacious at improving adherence to interferon beta-1a
therapy after 4 months compared with usual care for
depression (Mohr et al., 2000).
6.5. Theme 5: empowering through a sense of
responsibility
The responsibility to engage the MS patient in their health lies
with everyone involved with their care, as well as with the
patient themselves. Harnessing this sense of responsibility on
all levels may be instrumental in empowering engagement.
In an attempt to provide a comprehensive picture of the
demands imposed upon the individual by current healthcare
delivery practices in the USA, the US Center for Advancing
Disease developed a national Engagement Behavior Frame-
work (Table A2 Appendix) (Center for Advancing Health,
2014). On a clinical level, the framework serves to help the
patient understand the extent to which they need to
become involved to leverage healthcare resources, which
could help galvanize the patient into action. It could also
help identify areas that are difﬁcult for the patient to
achieve and a platform for discussing these concerns with
the physician. On a system level, it helps highlight the scope
of challenges facing patients in maximizing their care,
identiﬁes knowledge gaps, sets priorities for new research
and commissions reviews to consolidate knowledge (Center
for Advancing Health, 2014). Bernabeo et al. (2013) have
also published a set of key competencies that are required
on a patient, physician and system level in order to achieve
shared decision-making (Bernabeo and Holmboe, 2013).
Whether a patient becomes engaged in their care is a choice
for the individual but considering the beneﬁts to the patient,
encouraging engagement is ethically sound. Instilling a sense of
societal responsibility in the patient might be beneﬁcial – with
regard to their responsibility to use the resources available in
the most responsible manner. Some patients – for example, the
‘pragmatic’, ‘consistent’ or ‘hungry’ patient (Table 2) – may
feel more engaged in their care if they are involved on a meso
or macro level, becoming involved in drug development,
healthcare policies, patient advocacy/support, fundraising,
and local MS Society activities. Initiatives such as the FDA
Patient Network (http://patientnetwork.fda.gov/) and the MS
Society's Research Network (http://www.mssociety.org.uk/ms-
research/get-involved-research/research-network/whats-in
volved) provide avenues through which some patients may gain
empowerment. A sense of responsibility may also be fostered
by a patient becoming a patient-educator for other patients or
medical professionals. This has been shown to be a rewarding
and therapeutic experience (Anderson et al., 2003; Muir, 2007),
with beneﬁts such as raising self-esteem and empowerment,
gaining new insights into their own issues, fostering a better
understanding of the patient–doctor relationship, companion
ship, and improved QoL (Towle et al., 2010; Gecht, 2000;
Walters et al., 2003). However, the patient needs support in
managing the potential challenges of undertaking such a role
(Lauckner et al., 2012). Lay or community teaching is evolving
and becoming an accepted method of teaching patient-
centric care. In some countries, such as the UK, patient
involvement in health professional education is mandated by
the government.
7. Discussion
By its nature, this paper is selective in its approach and its
themes represent the primary thoughts of the MS in the 21st
Century Steering Group in relation to topics that have the
potential to inﬂuence patient engagement in MS.
Whilst appreciation has been accumulating for the criti-
cal role played by the patient in the effectiveness of
healthcare, we are now observing a shift in the way patients
are being compelled to get involved in the healthcare
process, and this has the potential to become a strong
framework for achieving patient engagement. PROs are
becoming more integral to clinical trial protocols, manage-
ment guidelines are becoming more reﬂective of patient-
centric issues, and therapeutic patient education for
chronic conditions has found legal sanction in some coun-
tries. Yet, what appears to make a critical difference to a
patient's experience of MS is their personal relationship with
their healthcare provider. This is the central foundation of
patient-centeredness and the key to motivating a patient to
be engaged in their own care.
However, developing rapport takes time, which is not cur-
rently afforded to physicians on a consistent basis under current
healthcare systems. Time constraints remain the most frequently
cited barrier to implementing the process of shared decision-
making in the clinical setting (Gravel et al., 2006) – and indeed to
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any change in clinical practice (Legare and Witteman 2013).
Hence, promotion of effective integration of patient engagement
requires commitment from those developing healthcare systems.
In addition to time constraints, increasing pressure is being
placed on physicians to acquire further competencies to aid
patient engagement. Integration of such skills into medical
training is likely to be a worthwhile endeavor. However,
healthcare organizations and policy makers need to analyze
the ways in which their policies are preventing patient engage-
ment from currently succeeding. Certainly, further research is
required to explore the impact of payment schemes to promote
integrated chronic care and ﬁnancially support patient engage-
ment (Tsiachristas et al., 2013). While we recognize that
implementing procedures and policies to positively inﬂuence
patient engagement takes additional resources, achieving this
from an early stage will likely improve healthcare efﬁciency in
terms of patient (and healthcare professional) satisfaction,
clinical outcomes, costs, and time.
As well as ﬁnancial and policy constraints, the prevailing
social and cultural environment is also likely to impact
considerably on the emphasis of shared decision-making
and, consequently, patient engagement. Particularly in an
age of multiculturalism, patients and their physicians can
bring a mixture of social and cultural-speciﬁc ideas and
values to the medical interaction, and to their thoughts and
expectations as to how health should be managed. Physi-
cians can help transcend these differences by learning
about the social and cultural beliefs of their patients,
remaining non-judgmental when differences arise, and by
paying close attention to signals of discontent or lack of
engagement from the patient.
The way in which patients engage in their healthcare is very
personal and will ﬂuctuate throughout the course of the
disease but is critical to optimizing healthcare beneﬁts. This
is a challenging role that requires the patient to be motivated,
insightful and aware, which will not always be possible
throughout the course of the disease. The role of the
healthcare professional, and critically the MS nurse, is to help
support the patient in this engaged role. The consequences of
patients not engaging will be borne most heavily by the
patients themselves and their families, in the form of emo-
tional, physical, social and ﬁnancial costs; but it also impacts
heavily on healthcare systems and society with respect to
wasted resources, suboptimal outcomes and increases in
health disparities. All stakeholders need to demonstrate an
ongoing commitment to ensure that every MS patient takes
the opportunity to participate appropriately in their care.
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Table A1 Interventions shown to support shared decision-making and health literacy: study ﬁndings (Coulter, 2012).
Intervention Study ﬁndings
Shared decision making
Patient decision aids  Numerous randomized trials indicate that patient decision aids
improve decision quality and prevent overuse of options that
informed patients do not value. Therefore, they have a potential
role in reducing unwarranted variations in the use of preference-
sensitive health-care options (O'Connor et al., 2009).
Health coaching  Targeted coaching can have a beneﬁcial effect on risk factors and
health outcomes, and improvements in health behaviors (Clark
et al., 2010; Hutchison and Breckon 2011; Neubeck et al., 2009)
Question prompts  Can help increase the number of questions asked in a consultation
but does not necessarily improve patient knowledge (Gaston and
Mitchell 2005; Harrington et al., 2004; Kinnersley et al., 2007;
Wetzels et al., 2008)
Self-management education and support  Can improve knowledge, coping behavior, adherence to treatment
recommendations, and self-efﬁcacy (Chodosh et al., 2005; Foster
et al., 2007)
Health literacy
Personalized patient information (paper and
electronic)reinforced by professional or lay
support
 Improves patient knowledge and understanding of their disease
(Kinnersley et al., 2007; Stacey et al., 2011).
 Targeted, well-designed interventions can help increase knowledge
and understanding in people with low levels of health literacy
(Pignone et al., 2005)
 Can help increase sense of empowerment, ability to cope and
reduce anxiety (Bessell et al., 2002; Eysenbach 2003; Eysenbach
et al., 2004; Wofford et al., 2005)
Telephone counseling and help lines  Can reduce isolation, increase decision-making conﬁdence, and
improve satisfaction (Jennett et al., 2003; Mair and Whitten, 2000).
Motivational interviewing  A systematic review of 72 studies found that motivational
interviewing in a scientiﬁc setting to stimulate healthy behaviors,
outperforms traditional advice-giving in the treatment of a broad
range of behavioral problems and diseases (Rubak et al., 2005).
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Table A2 Engagement Behavior Framework devised by the US Center for Advancing Disease – a qualitative description of
behaviors that US patients must perform to optimally beneﬁt from their care (Center for Advancing Health 2014).
1. Find safe, decent care  Find provider(s) who meet personal criteria (eg performance, cost, geographic access,
personal style), will take new patients and accept personal insurance
 Use available comparative performance information (including cost data) to identify
prospective providers
 Establish a relationship with a healthcare professional or group
 Seek and use the appropriate healthcare setting when professional attention is required
2. Communicate with healthcare
professionals
 Prepare in advance of out-patient and in-patient contact, list of questions/issues for
discussion with the healthcare professional
 Bring list of all current medications (including supplements and alternative products)
and be prepared to discuss their beneﬁts and side effects
 Report accurately on the history and current status of physical and mental symptoms
 Ask questions when any explanations or next steps are not clear and express any
concerns about recommendations or care experiences
3. Organize healthcare  Make appointments; inquire about no-show policies; arrive on time
 Assess whether facility can accommodate unique needs (eg physical navigation, hearing
or visual impairment, translation services) and arrange for assistance
 Bring documentation of health insurance coverage
 Bring another person to assist patient if frail, confused, unable to move around or unable
to remember the conversation with the provider
 Bring a summary of medical history, current health status and recent test results to visits
as appropriate
 Ensure that relevant medical information is conveyed between providers and institutions
 Obtain all test results and appointment records, and maintain personal health record
4. Pay for healthcare  Compare insurance coverage options, match to personal values, needs and preferences,
and select coverage
 Gather and submit relevant eligibility documentation if applying for or seeking to
maintain public insurance (eg Medicaid, Medicare, SCHIP), compare coverage options if
applicable, match to patient's own values, needs and preferences, and select coverage
 Before seeking treatment: ascertain cost, beneﬁt coverage restrictions and incentives
such as mental health beneﬁts limitations, pre-certiﬁcation requirements, access
restrictions to specialists or adjunct health providers, variables in co-pays for speciﬁc
types of care or providers
 Maintain or adjust coverage in the event of unemployment, eligibility or family status
changes (ie change of job, marriage, divorce, birth of child)
 Maintain all receipts for drugs, devices and services; submit any documentation of
services and/or payments upon request or as needed for third-party payers (eg private
insurance, medical/ﬂexible health savings accounts or public payers) and submit
payment; negotiate schedule and amount if necessary
5. Make good treatment
decisions
 Gather additional expert opinions on any serious diagnosis prior to beginning any course
of treatment
 Ask about the evidence for the efﬁcacy of recommended treatment options (risks and
beneﬁts)
 Evaluate treatment options
 Negotiate a treatment plan with the provider(s)
6. Participate in treatment  Learn about any newly prescribed medications and devices, including possible side
effects or interactions with existing medications and devices
 Fill or reﬁll prescriptions on time, monitor medication effectiveness and consult with
prescribing clinician before discontinuing use
 Maintain devices
 Evaluate and receive recommended diagnostic/follow-up tests in discussion with
healthcare providers
 Monitor symptoms/condition, including danger signs that require urgent attention (eg
for diabetes – monitor glucose regularly, check feet; for depression – medication and/or
counseling and monitor symptoms; for hypertension – measure blood pressure regularly,
maintain blood pressure diary)
7. Promote health  Set priorities for changing behavior to optimize health and prevent disease, and act
on them
 Identify and secure services that support changing behavior to maximize health and
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